• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Impact of obesity on annual medical expenditures and diabetes care in Japanese patients with type 2 diabetes mellitus.肥胖对日本 2 型糖尿病患者的年度医疗支出和糖尿病治疗的影响。
J Diabetes Investig. 2018 Jul;9(4):776-781. doi: 10.1111/jdi.12766. Epub 2017 Nov 22.
2
Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status.按糖尿病状况划分的美国肥胖成年人中,与体重指数降低相关的医疗支出节省情况。
Pharmacoeconomics. 2015 Jul;33(7):707-22. doi: 10.1007/s40273-014-0230-2.
3
The Burden of Obesity on Diabetes in the United States: Medical Expenditure Panel Survey, 2008 to 2012.美国肥胖对糖尿病的影响:2008年至2012年医疗支出小组调查
Value Health. 2017 Jan;20(1):77-84. doi: 10.1016/j.jval.2016.08.735. Epub 2016 Nov 4.
4
Clinical features of normal weight Japanese patients with type 2 diabetes who had formerly been obese.临床特点正常体重的日本患者 2 型糖尿病谁以前肥胖。
J Atheroscler Thromb. 2011;18(2):115-21. doi: 10.5551/jat.5926. Epub 2010 Nov 6.
5
Medical expenditures associated with major depressive disorder among privately insured working-age adults with diagnosed diabetes in the United States, 2008.美国有诊断糖尿病的私营保险工作年龄成年人中,与重度抑郁症相关的医疗支出,2008 年。
Diabetes Res Clin Pract. 2013 Apr;100(1):102-10. doi: 10.1016/j.diabres.2013.02.002. Epub 2013 Mar 13.
6
Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age.青年期和中年期的体重指数与老年期医疗保险支出的关系。
JAMA. 2004 Dec 8;292(22):2743-9. doi: 10.1001/jama.292.22.2743.
7
Obesity and expenditures among elderly Veterans Health Administration users with diabetes.老年退伍军人管理局糖尿病患者的肥胖症和支出。
Popul Health Manag. 2009 Oct;12(5):255-64. doi: 10.1089/pop.2008.0022.
8
Obesity and health expenditures: evidence from Australia.肥胖与医疗支出:来自澳大利亚的证据。
Econ Hum Biol. 2015 Apr;17:42-58. doi: 10.1016/j.ehb.2015.01.001. Epub 2015 Jan 16.
9
Resource use and costs in patients with poorly controlled type 2 diabetes mellitus and obesity in routine clinical practice in Spain.在西班牙常规临床实践中,治疗控制不佳的 2 型糖尿病伴肥胖症患者的资源利用和成本。
Curr Med Res Opin. 2020 Sep;36(9):1449-1456. doi: 10.1080/03007995.2020.1793749. Epub 2020 Jul 23.
10
Obesity and people with disabilities: the implications for health care expenditures.肥胖与残疾人士:对医疗支出的影响。
Obesity (Silver Spring). 2013 Dec;21(12):E798-804. doi: 10.1002/oby.20531. Epub 2013 Sep 5.

引用本文的文献

1
Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model validation.评估东亚人群肥胖相关并发症的健康和经济负担:日本核心肥胖模型中风险方程的应用及模型验证
BMJ Public Health. 2024 Jul 12;2(1):e000302. doi: 10.1136/bmjph-2023-000302. eCollection 2024 Jun.
2
Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes from Japanese Payer Perspective.从日本医保支付方角度看非奈利酮治疗2型糖尿病合并慢性肾脏病的成本效益分析
Adv Ther. 2025 Feb;42(2):995-1008. doi: 10.1007/s12325-024-03084-5. Epub 2024 Dec 17.
3
Cost-effectiveness of behavioural counselling intervention compared with non-intervention for adult patients with metabolic syndrome to prevent cardiovascular diseases and type 2 diabetes in Japan: a microsimulation modelling study.行为咨询干预与非干预对日本代谢综合征成年患者预防心血管疾病和 2 型糖尿病的成本效益比较:微观模拟模型研究。
BMJ Open. 2024 Apr 5;14(4):e072688. doi: 10.1136/bmjopen-2023-072688.
4
Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes in the SUSTAIN 1, 2, 5 and 9 trials: Post-hoc analysis.SUSTAIN 1、2、5 和 9 项临床试验中的一周一次司美格鲁肽在日本 2 型糖尿病患者中的疗效和安全性:事后分析。
J Diabetes Investig. 2022 Dec;13(12):1971-1980. doi: 10.1111/jdi.13905. Epub 2022 Oct 12.
5
Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index.每周一次司美格鲁肽在日本 2 型糖尿病患者中的疗效和安全性:基于基线年龄和体重指数的亚组分析。
J Diabetes Investig. 2022 Jul;13(7):1161-1174. doi: 10.1111/jdi.13773. Epub 2022 Mar 9.
6
Effect of a mobile digital intervention to enhance physical activity in individuals with metabolic disorders on voiding patterns measured by 24-h voided volume monitoring system: Kumejima Digital Health Project (KDHP).移动数字干预对代谢紊乱个体的体力活动增强作用对 24 小时排尿量监测系统测量的排尿模式的影响:久米岛数字健康项目(KDHP)。
Int Urol Nephrol. 2021 Aug;53(8):1497-1505. doi: 10.1007/s11255-021-02867-x. Epub 2021 Apr 28.
7
The Trends of Medical Care Expenditure with Adjustment of Lifestyle Habits and Medication; 10-Year Retrospective Follow-Up Study.生活方式习惯与药物调整对医疗支出的趋势影响:10 年回顾性随访研究。
Int J Environ Res Public Health. 2020 Dec 20;17(24):9546. doi: 10.3390/ijerph17249546.
8
Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46).日本2型和1型糖尿病患者中糖尿病肾病、视网膜病变和神经病变的下降趋势与糖尿病护理指标的改善(JDDM 46)
BMJ Open Diabetes Res Care. 2018 May 29;6(1):e000521. doi: 10.1136/bmjdrc-2018-000521. eCollection 2018.

本文引用的文献

1
Trends in medical performance in diabetic patients in primary care clinics compared with those in hospitals: Shiga Diabetes Clinical Survey, Japan, 2000-2012.与医院相比,基层医疗诊所糖尿病患者的医疗表现趋势:日本滋贺糖尿病临床调查,2000 - 2012年
Diabetol Int. 2016 Jul 26;8(1):59-68. doi: 10.1007/s13340-016-0280-0. eCollection 2017 Mar.
2
Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白 2 抑制剂对 2 型糖尿病患者心肾保护的代谢和血液动力学效应。
J Diabetes Investig. 2017 Jul;8(4):416-427. doi: 10.1111/jdi.12644. Epub 2017 May 12.
3
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.靶向肾脏葡萄糖重吸收以治疗高血糖:SGLT2抑制剂的多效性作用
Diabetologia. 2017 Feb;60(2):215-225. doi: 10.1007/s00125-016-4157-3. Epub 2016 Nov 22.
4
Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40).2型糖尿病患者血糖、血压和血脂达标率及并发症患病率的大规模调查(日本糖尿病学会杂志40)
BMJ Open Diabetes Res Care. 2016 Oct 3;4(1):e000294. doi: 10.1136/bmjdrc-2016-000294. eCollection 2016.
5
Urinary Potassium Excretion and Renal and Cardiovascular Complications in Patients with Type 2 Diabetes and Normal Renal Function.2型糖尿病且肾功能正常患者的尿钾排泄与肾脏及心血管并发症
Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2152-8. doi: 10.2215/CJN.00980115. Epub 2015 Nov 12.
6
Impact of population aging on trends in diabetes prevalence: A meta-regression analysis of 160,000 Japanese adults.人口老龄化对糖尿病患病率趋势的影响:对16万日本成年人的荟萃回归分析
J Diabetes Investig. 2015 Sep;6(5):533-42. doi: 10.1111/jdi.12333. Epub 2015 Mar 2.
7
Pioglitazone treatment and cardiovascular event and death in subjects with type 2 diabetes without established cardiovascular disease (JDDM 36).吡格列酮治疗与无确诊心血管疾病的2型糖尿病患者的心血管事件及死亡(日本糖尿病学会杂志36)
Diabetes Res Clin Pract. 2015 Sep;109(3):485-92. doi: 10.1016/j.diabres.2015.06.005. Epub 2015 Jul 16.
8
Trends in health care expenditure in U.S. adults with diabetes: 2002-2011.2002 - 2011年美国成年糖尿病患者的医疗保健支出趋势
Diabetes Care. 2015 Oct;38(10):1844-51. doi: 10.2337/dc15-0369. Epub 2015 Jul 22.
9
Change in medical spending attributable to diabetes: national data from 1987 to 2011.糖尿病导致的医疗支出变化:1987 年至 2011 年的全国数据。
Diabetes Care. 2015 Apr;38(4):581-7. doi: 10.2337/dc14-1687. Epub 2015 Jan 15.
10
Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status.按糖尿病状况划分的美国肥胖成年人中,与体重指数降低相关的医疗支出节省情况。
Pharmacoeconomics. 2015 Jul;33(7):707-22. doi: 10.1007/s40273-014-0230-2.

肥胖对日本 2 型糖尿病患者的年度医疗支出和糖尿病治疗的影响。

Impact of obesity on annual medical expenditures and diabetes care in Japanese patients with type 2 diabetes mellitus.

机构信息

Department of Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.

Kusatsu General Hospital, Kusatsu, Shiga, Japan.

出版信息

J Diabetes Investig. 2018 Jul;9(4):776-781. doi: 10.1111/jdi.12766. Epub 2017 Nov 22.

DOI:10.1111/jdi.12766
PMID:29068148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6031508/
Abstract

AIMS/INTRODUCTION: Diabetes and obesity are important health and economic concerns. We investigated the influence of obesity on diabetes control, the annual medical expenditures and medications in Japanese patients with type 2 diabetes who were relatively lean in comparison with those in Western countries.

MATERIALS AND METHODS

A total of 402 Japanese patients with type 2 diabetes were enrolled and their annual medical expenditures investigated. Obesity was defined as body mass index ≥25 kg/m , according to the obesity classifications from the Japan Society for the Study of Obesity.

RESULTS

A total of 165 patients (41.0%) were classified as obese. The obese group was younger, had poor glycemic control and higher frequency of hypertension than the non-obese group. The median total annual medical expenditures for all participants was ¥269,333 (interquartile range ¥169,664-437,437), which was equivalent to approximately $US2,450. The annual medical expenditure was significantly higher in patients with obesity than in non-obese patients (P < 0.001). This difference was mainly attributed to the annual expenditures for medication and hospitalization. In particular, the medication expenditures and the average number of drug classes for hyperglycemia and hypertension were significantly higher in the obese group.

CONCLUSIONS

Japanese patients with type 2 diabetes and obesity had higher annual medical expenditures and a larger number of medications, but their diabetes control care was insufficient in comparison with those without obesity. Further studies are required to assess the effect of reducing bodyweight on diabetes control and costs.

摘要

目的/引言:糖尿病和肥胖是重要的健康和经济问题。我们研究了肥胖对日本 2 型糖尿病患者糖尿病控制、年医疗支出和药物治疗的影响,这些患者与西方国家的患者相比相对较瘦。

材料和方法

共纳入 402 例日本 2 型糖尿病患者,调查其年医疗支出。根据日本肥胖学会的肥胖分类标准,将肥胖定义为体重指数≥25kg/m²。

结果

共有 165 例(41.0%)患者被归类为肥胖。与非肥胖组相比,肥胖组年龄较小,血糖控制较差,高血压发生率较高。所有参与者的总年医疗支出中位数为 269333 日元(四分位距 169664-437437),相当于约 2450 美元。肥胖患者的年医疗支出明显高于非肥胖患者(P<0.001)。这种差异主要归因于药物治疗和住院治疗的年度支出。特别是,肥胖组在治疗高血糖和高血压的药物支出和平均药物种类方面明显更高。

结论

与无肥胖的患者相比,日本 2 型糖尿病合并肥胖患者的年医疗支出更高,用药更多,但糖尿病控制护理不足。需要进一步研究来评估减轻体重对糖尿病控制和成本的影响。